key: cord-0946793-8zmi7c44
authors: Nunes, José Pedro L.
title: Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review
date: 2020-11-11
journal: Porto Biomed J
DOI: 10.1097/j.pbj.0000000000000085
sha: 61a79072e73eab0952f9e09afc1d63a0b6e4889d
doc_id: 946793
cord_uid: 8zmi7c44

BACKGROUND: Interest exists concerning the use of angiotensin-converting enzyme inhibitors (ACEis) in patients with COVID-19 disease. OBJECTIVES: The aim of the study was to perform a systematic review on mortality associated to the use of ACEi in patients with COVID-19 disease. METHODS: Search in Medline (PubMed), in ISI Web of Knowledge and in medRxiv database; use of other sources. RESULTS: A total of 33 articles were evaluated. Concerning the papers used to produce the meta-analyses, 7 studies were selected, 5 of which were used. These 5 studies involved a total number of 944 patients treated with ACEi and 5173 not treated with ACEi. Increased mortality was seen in association to the use of ACEi in the context of COVID-19 disease (ACEi users vs nonusers; odds ratio, 1.48; 95% confidence interval, 1.02–2.15; P = .04). When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different (odds ratio, 0.96; 95% confidence interval, 0.76–1.21; P = .74). Concerning the remaining reports, different types of data adjustments were used by several authors, after which increased mortality was not seen in association to the use of ACEi in this context. CONCLUSIONS: ACEi use could act as a marker of increased mortality risk in some but not all COVID-19 disease settings. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in COVID-19 patients, to establish the safety of ACEi use in this context.

An epidemic of viral disease caused by a new Coronavirus, Sars-Cov-2, is currently underway in most regions of the world. There is interest concerning angiotensin-converting enzyme inhibitors (ACEis) use in this context, since the virus appears to interact with the angiotensin-converting enzyme type 2 (ACE2). 1 Although ACEi and angiotensin receptor blockers (ARBs) are sometimes evaluated together, they do not have a common mechanism of action, and therefore a separate evaluation of ACEi use in this context may be of interest. In the present report, a systematic review was carried out, looking at published reports studying the association between ACEi use and mortality in patients with COVID-19, the disease caused by the new Coronavirus. The aim of the study was to use currently available data to tentatively evaluate if a relation exists between ACEi use and patient mortality in this context.

The study started with a search on Medline (PubMed), in ISI Web of Knowledge and in medRxiv databases, using the query "Covid-19" AND "ACE inhibitor" AND "mortality" (first query) and "Covid-19" AND "angiotensin-converting enzyme inhibitor" AND "mortality" (second query). The search took place on June 16 to 21, 2020, and no articles were excluded based on publication date. The queries resulted in different sets of articles being found, as presented in Figure 1 , prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Further additional studies were identified in other relevant sources, including the sites of major medical journals (Fig. 1 ).

Only human studies with original data were included.

Excluded were mechanistic studies; animal studies; case reports; editorials; review papers; study protocols; duplicate studies, if found; systematic reviews and/or meta-analyses; guidelines; and genetic or pathological studies.

Meta-analysis was carried out by using the Comprehensive Metaanalysis Software, V.2.0 (Biostat, New Jersey). Fixed effects or random effects analyses were carried out, depending on the degree of heterogeneity of the data (fixed effects for I squared values <50; random effects otherwise). Mortality was the only parameter under study, and the odds ratio was calculated. A level of significance of 0.05 was used.

Global article quality assessment was carried out according to the method used by Haffar et al, 2 concerning the articles used for the meta-analyses.

A total of 33 articles were identified and selected for further study (listed in Supplementary Table 1 ; http://links.lww.com/PBJ/A5).

A number of articles failed to include the data of interest for the present purpose, and this was the major reason to exclude reports from entering meta-analyses. The precise number of deaths or specific information on ACEi users were among the data not presented in some reports.

One article, initially selected, was retracted by the authors on June 4, 2020, and was therefore excluded, leaving a total of 7 selected studies. Two of the selected reports (presented in Table 1 ) had no fatalities in one of the groups, making these data unsuitable to be used by the meta-analysis software. 3, 4 Five studies were used to produce the metaanalyses [5] [6] [7] [8] [9] (Figs. 2 and 3 ). These 5 studies involved a total number of 944 patients treated with ACEi and 5173 not treated with ACEi. The main results concerning ACEi use and mortality are presented in Table 1 . Some reports presented data concerning only hypertensive patients, whereas others did not (Table 1 ). Nunes Porto Biomed. J. (2020) 5:6 www.portobiomedicaljournal.com

Increased mortality was seen in association to the use of ACEi in the context of COVID-19 disease [ACEi users vs nonusers; random effects; odds ratio, 1.48; 95% confidence interval (CI), 1.02-2.15; P = .04; Fig. 2 ].

When compared to mortality in patients treated with ARBs, mortality of patients treated with ACEi was not significantly different (fixed effects, odds ratio, 0.96; 95% CI, 0.76-1.21; P = .74; Fig. 3 ).

The population studied in the selected reports had different mean or median patient ages (Table 1 ). Overall mortality also differed when the selected reports were compared, with mortality rates ranging from <10% to >20% (Table 1) .

The 5 reports used for the meta-analyses were evaluated for global quality, and the results are presented in the Supplementary Table 2 ; http://links.lww.com/PBJ/A5. 2 Giorgi Rossi et al 6 indicate a numerical increase in mortality with previous ACEi use, although the authors carried out a data adjustment for age, sex, and Charlson Comorbidity Index, and state that "previous use of ACE inhibitors has no effect on risk of death (hazard ratio 0.97, 95% CI 0.69-1.34)". Richardson et al 5 also show a numerical increase in mortality with ACEi use. Bravi et al 9 stated that "In multivariable analyses restricted to hypertensive subjects . . . , the treatment with ARBs and/or ACE inhibitors never increased the likelihood of severe or very severe/lethal disease".

A number of reports presented data on ACEi and/or ARB use in COVID-19 patients but did not contain data that could be used for the meta-analyses (listed in Supplementary Table 1 ; http:// links.lww.com/PBJ/A5; some of which presented below).

Feng et al 10 reported on 476 patients from China, and stated that "more patients were taking ACEis/angiotensin II receptor blockers in the moderate group than in the severe and critical groups." Huang et al 11 reported on 50 hospitalized hypertension patients, and stated that there was no significant difference in clinical severity, clinical course, and in-hospital mortality between patients either taking or not taking renin-angiotensin system blocking drugs. Zhang et al 12 reported on 1128 adult patients with hypertension, and stated that "inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers." These authors used adjusted data, ARB users were in greater number (157 patients) than ACEi users (31 patients) and 34% of patients with hypertension did not receive antihypertensive drugs during hospitalization. 12 Zhou et al 13 reported on a lower death rate in Porto Biomedical Journal association to in-hospital use of ACEi or ARB therapy in COVID-19 patients with hypertension, coronary artery disease, or both. Bean et al 14 reported on 1200 patients from the United Kingdom, and 399 COVID-19 patients were taking ACEi or ARB. The primary endpoint of death or transfer to a critical care unit was reached less often in this latter group (adjusted data).

Mancia et al 15 reported on 6272 COVID-19 patients from Italy, as well as on a control population. The authors showed that both ARB and ACEi were more frequently prescribed in case patients than in controls. After adjustment, ARB and ACEi had no significant association with the risk of COVID-19 disease.

The report by Ip et al 16 Khera et al 19 studied both an outpatient and an inpatient cohort of hypertensive patients with COVID-19 disease, based on administrative data. The use of ACEi was not associated to an increased mortality risk. 19 

In the present report, a systematic review was carried out, concerning the use of ACEi and a possible association to a change in mortality in COVID-19 disease. Only observational reports were found, with no clinical trial data.

In the meta-analysis, ACEi use was associated to increased mortality in the setting of COVID-19 disease. ACEi use could act as a marker of increased mortality risk in patients with COVID-19 disease-even if not causally related. ACEi use could act as a proxy for the presence of arterial hypertension, and perhaps also for the presence, in patients with arterial hypertension, of further medical conditions with an increased mortality risksuch as heart failure, chronic kidney disease, coronary artery disease, or atrial fibrillation. 20 ACEi are also used in patients with these conditions in the absence of hypertension.

Arterial hypertension has been shown to act as a marker of increased mortality risk in COVID-19 disease. 21 The age difference seen in the populations studied by the various authors could modulate the effects of ACEi use in this context. Aging is associated to an increased low-grade chronic inflammatory state, 22 decreased muscle mass, increased adiposity, and a state of immune dysregulation. In COVID-19 disease, an increase in inflammatory mediators is seen in patients with more severe disease. 23 Increasing age is a known major factor for mortality in COVID-19 disease. 23 A number of other reports under analysis failed to show increased mortality associated to ACEi use in the setting of COVID-19 disease, after different types of statistical manipulation of data, and there were even reports presenting favorable results. 13, 16 Should patients discontinue ACE inhibitor therapy out of a concern that they are at increased risk during the COVID-19 pandemic? 24 The evidence currently available does not allow an answer to be given on a firm ground-neither a negative nor a positive one. These drugs may act as markers of increased risk in some but not all COVID-19 disease settings, but that does not mean causality exists.

Limitations of the present report are very important. Not only are all the data reviewed of an observational character, but significant differences exist when the different reports are compared, both in reports entering the meta-analyses (as shown in Table 1 ) and in the remaining reports under evaluation.

Several types of bias could exist in the reports under study. Clear limitations would exist concerning the possible use of the nonadjusted data under review to infer causality. The interpretation of adjusted data, which point in the direction that the use of ACEi was not independently associated with increased mortality, has the limitation that different types of statistical manipulation of data were used by different authors (meaning that other types of data manipulation could lead to different results).

Significant differences exist between mortality rates associated to COVID-19 disease in different countries. The same happens with patterns of antihypertensive drug use.

In conclusion, ACEi use could act as a marker of increased mortality risk in some but not all COVID-19 disease settings. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in COVID-19 patients, to establish the safety of ACEi use in this context.

No funding received for the preparation of this text.

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Acute liver failure caused by hepatitis E virus genotype 3 and 4: a systematic review and pooled analysis

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Association of renin-angiotensinaldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

The Reggio Emilia COVID-19 Working GroupCharacteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia

Association of reninangiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China

Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives

Predictors of severe or lethal COVID-19, including angiotensin converting enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens

COVID-19 with different severities: a multicenter study of clinical features

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Association of inpatient use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19

Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality

ACE-inhibitors and angiotensin-2 receptor blockers are not associated with severe SARS-COVID19 infection in a multi-site UK Acute Hospital Trust

Reninangiotensin-aldosterone system blockers and the risk of Covid-19

Hypertension and renin-angiotensinaldosterone system inhibitors in patients with Covid-19. medRxiv

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Renin-angiotensinaldosterone system inhibitors and risk of COVID-19

Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with coronavirus disease-19. medRxiv

ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Redefining chronic inflammation in aging and age-related diseases: proposal of the senoinflammation concept

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Inhibitors of the renin-angiotensin-aldosterone system and COVID-19

None to report.